<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04676321</url>
  </required_header>
  <id_info>
    <org_study_id>IRST 162.13</org_study_id>
    <nct_id>NCT04676321</nct_id>
  </id_info>
  <brief_title>Key Performance Indicators for the Assessment of NSCLC Patients Pathway</brief_title>
  <acronym>KIND</acronym>
  <official_title>Key Performance Indicators for the Assessment of Diagnostic and Therapeutic Pathway of NSCLC Patients: a Multicenter Study (KIND NSCLC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Azienda Unità Sanitaria Locale Reggio Emilia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Azienda Ospedaliera Universitaria Policlinico</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, observational study involving a retrospective collection of data. A&#xD;
      total of potential 16 key performance indicators (KPIs) had been developed from a panel of&#xD;
      experts (clinicians, IT experts, etc..) to investigate the appropriateness of care in NSCLC&#xD;
      patients, with a special focus on the use of immunotherapy. The eligible population and data&#xD;
      will be gathered retrospectively using an algorithm. Administrative databases will be used as&#xD;
      unique resource: to identify target population and to collect patient's data with which&#xD;
      measure KPIs.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-center, observational study involving retrospective collection of NSCLC&#xD;
      patients information. All consecutive patients who had a newly diagnosis of NSCLC in 2017&#xD;
      from healthcare administrative database between January 2017 and December 2017, identified&#xD;
      through the proposed algorithm, will be considered. All data needed for KPI calculation, even&#xD;
      if they fall outside January-December 2017 period, will be collected. The end of data&#xD;
      collection will be defined as patient death or 30 June 2018, whichever came first.&#xD;
&#xD;
      A set of potential KPIs had been developed from a panel of experts (clinicians, IT experts&#xD;
      etc..) to investigate the appropriateness of activities within NSCLC care pathway, with a&#xD;
      special focus on the use of immunotherapy. The following KPIs will be measured to investigate&#xD;
      the appropriateness of NSCLC patient care pathways, with a special focus on the use of&#xD;
      immunotherapy:&#xD;
&#xD;
        1. Percentage of patients who performed biopsy within 7 days from the date of examination&#xD;
           prescription;&#xD;
&#xD;
        2. Percentage of metastatic NSCLC patients at diagnosis;&#xD;
&#xD;
        3. Percentage of major surgical resections within the year of analysis;&#xD;
&#xD;
        4. Percentage of surgical patients on the total number of patients with exploratory&#xD;
           thoracotomy in inpatient setting;&#xD;
&#xD;
        5. Percentage of patients undergoing neoadjuvant therapy ( CT or CT+RT within 6 months&#xD;
           prior to the first major resection date;&#xD;
&#xD;
        6. 30-day mortality rate from major surgery;&#xD;
&#xD;
        7. Percentage of patients discussed in the multidisciplinary team (MDT) meeting at least&#xD;
           once in the year of incidence;&#xD;
&#xD;
        8. Percentage of patients who performed imaging exams such as MRI, TC and PET within 7 days&#xD;
           from MDT meeting;&#xD;
&#xD;
        9. Average and range of length of stay;&#xD;
&#xD;
       10. Average time between biopsy and the first administration of systematic anti-cancer drug;&#xD;
&#xD;
       11. Percentage of patients treated with immunotherapies;&#xD;
&#xD;
       12. Percentage of patients who underwent immunotherapy for more than 6 months after first&#xD;
           dose;&#xD;
&#xD;
       13. Percentage of patients who underwent anti-cancer drug treatment in the last 30 days of&#xD;
           life;&#xD;
&#xD;
       14. Percentage of patients who underwent the first administration of systematic anticancer&#xD;
           drug within 30 days from discussed in MDT meeting;&#xD;
&#xD;
       15. Percentage of patients who underwent RT in the last 30 days of life ( excluded&#xD;
           palliative treatments single fraction);&#xD;
&#xD;
       16. Percentage of patients who underwent at least one Integrated Home Care (IHC);&#xD;
&#xD;
       17. Percentage of patients who underwent at least one hospice care;&#xD;
&#xD;
      The eligible population and data will be gathered retrospectively through an algorithm from&#xD;
      administrative databases (Hospital discharge cards, pharmaceutical databases as FED and AFT -&#xD;
      direct and territorial distribution, the regional register of mortality REM, the regional&#xD;
      register of outpatient specialist medical procedure ASA, the integrated home care IHC, and&#xD;
      SDHS-hospice). Administrative data will be used as unique resource to identify patients&#xD;
      cohort and to measure KPIs along care pathway. An evaluation of the NSCLC patients selection&#xD;
      algorithm will be performed on a sub-population using the electronic health record EHR as&#xD;
      gold standard.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 1, 2020</start_date>
  <completion_date type="Actual">November 15, 2020</completion_date>
  <primary_completion_date type="Actual">October 15, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Key Performance indicators</measure>
    <time_frame>six months</time_frame>
    <description>To measure a set of potential indicators (KPIs) derived from administrative database in order to investigate the appropriateness and quality of NSCLC care among participating sites.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Algorithm evaluatation</measure>
    <time_frame>two month</time_frame>
    <description>The secondary outcome is to develop and evaluate an algorithm to identify the eligible population of the study from administrative databases against to a clinical database. Algorithm will be used to identify study eligible patients and measure KPIs from hospital administrative databases.</description>
  </secondary_outcome>
  <enrollment type="Actual">430</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Patient pathway</intervention_name>
    <description>Investigation on the appropriateness and quality of NSCLC care among participating sites</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study population consisted of all adult patients (aged ≥ 18 years) residing in&#xD;
        Emilia-Romagna region, identified in the Hospital discharge card, who has been discharged&#xD;
        in any one of the participating sites (hospitals of Modena, Reggio-Emilia and Forlì-Cesena&#xD;
        provinces) with a newly diagnosis of Non small cell lung cancer between January and&#xD;
        December 2017.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - patients identified from hospital administrative databases of Emilia-Romagna region using&#xD;
        a case selection algorithm for identifying Non small cell lung cancer&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patients not residing in Emilia Romagna region (due to the difficulty in obtaining the&#xD;
             medical data).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mattia Altini, Master</last_name>
    <role>Principal Investigator</role>
    <affiliation>IRST</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>IRST</name>
      <address>
        <city>Meldola</city>
        <state>Forlì-Cesena</state>
        <zip>47014</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Arcispedale S.Maria Nuova</name>
      <address>
        <city>Reggio Emilia</city>
        <state>RE</state>
        <zip>42123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico of Modena</name>
      <address>
        <city>Modena</city>
        <zip>41125</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 15, 2020</study_first_submitted>
  <study_first_submitted_qc>December 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 21, 2020</study_first_posted>
  <last_update_submitted>December 15, 2020</last_update_submitted>
  <last_update_submitted_qc>December 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori</investigator_affiliation>
    <investigator_full_name>oriana nanni</investigator_full_name>
    <investigator_title>Biostatician</investigator_title>
  </responsible_party>
  <keyword>lung cancer</keyword>
  <keyword>NSCLC</keyword>
  <keyword>Administrative databases</keyword>
  <keyword>Algorithm</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 19, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/21/NCT04676321/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

